MSB 3.76% $1.03 mesoblast limited

Cell Therapy News/Articles, page-17701

  1. 2,646 Posts.
    lightbulb Created with Sketch. 1699
    Nice one Wilbs

    As opposed to the 2nd study of Kurtzberg
    et al. (42), patient population in our study were highly pretreated and
    refractory to previous treatments, which might have worsened
    response.Some authors (42, 44, 49) have also showed that, when
    MSCs were applied in an earlier stage of SR-aGVHD, the CR rates
    were higher.
    For example, Le Blanc et al. (42), in their study of a
    group of SR grade II-IV patients, described 55% CR and 16% PR.
    For that reason, taking into account the side effects of second line
    immunosuppression for GVHD and the good safety profile of MSCs
    (even in severely affected children), earlier use of MSCs therapy
    could be considered for patients with acute SR-GVHD.



    Reg

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.03
Change
-0.040(3.76%)
Mkt cap ! $1.170B
Open High Low Value Volume
$1.07 $1.07 $1.01 $13.19M 12.81M

Buyers (Bids)

No. Vol. Price($)
3 61090 $1.02
 

Sellers (Offers)

Price($) Vol. No.
$1.03 239558 5
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.